Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and i...

Full description

Bibliographic Details
Main Authors: Jan Yi-Yin, Hwang Tsann-Long, Chao Tzu-Chieh, Wu Pei-Yu, Yeh Chun-Nan, Lee Li-Yu, Wu Ting-Jung, Chen Miin-Fu
Format: Article
Language:English
Published: BMC 2006-10-01
Series:BMC Gastroenterology
Online Access:http://www.biomedcentral.com/1471-230X/6/29
id doaj-042833e649e9408abf7efc6935de0991
record_format Article
spelling doaj-042833e649e9408abf7efc6935de09912020-11-25T03:39:56ZengBMCBMC Gastroenterology1471-230X2006-10-01612910.1186/1471-230X-6-29Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylateJan Yi-YinHwang Tsann-LongChao Tzu-ChiehWu Pei-YuYeh Chun-NanLee Li-YuWu Ting-JungChen Miin-Fu<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and identify predictors for long-term disease-free survival (DFS) and overall survival (OS) to clarify the difference between high- and low-risk patients.</p> <p>Methods</p> <p>The clinicopathologic and follow-up records of 100 small intestine GIST patients who were treated at Chung Gung Memorial Hospital between 1983 and 2002 were retrospectively reviewed. Clinical and pathological factors were assessed for long-term DFS and OS by using a univariate log-rank test and a multivariate Cox proportional hazard model.</p> <p>Results</p> <p>The patients included 52 men and 48 women. Their ages ranged from 27 to 82 years. Among the 85 patients who underwent curative resection, 44 (51.8%) developed disease recurrence (liver metastasis was the most common form of recurrence). The follow-up period ranged from 5 to 202 months (median: 33.2 months). The 1-, 3-, and 5-year DFS and OS rates were 85.2%, 53.8%, and 43.7%, and 91.5%, 66.6%, and 50.5%, respectively. Using multivariate analysis, it was found that high tumor cellularity, mitotic count >5/50 high-power field, and a Ki-67 index ≧10% were three independent factors that were inversely associated with DFS. However, absence of tumor perforation, mitotic count < 5/50 high power field, and tumor with low cellularity were predictors of long-term favorable OS.</p> <p>Conclusion</p> <p>Tumors with low cellularity, low mitotic count, and low Ki-67 index, which indicate low risk, predict a more favorable DFS for small intestine GIST patients undergoing curative resection. Absence of tumor perforation with low mitotic count and low cellularity, which indicates low risk, can predict long-term OS for small intestine GIST patients who have undergone curative resection.</p> http://www.biomedcentral.com/1471-230X/6/29
collection DOAJ
language English
format Article
sources DOAJ
author Jan Yi-Yin
Hwang Tsann-Long
Chao Tzu-Chieh
Wu Pei-Yu
Yeh Chun-Nan
Lee Li-Yu
Wu Ting-Jung
Chen Miin-Fu
spellingShingle Jan Yi-Yin
Hwang Tsann-Long
Chao Tzu-Chieh
Wu Pei-Yu
Yeh Chun-Nan
Lee Li-Yu
Wu Ting-Jung
Chen Miin-Fu
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
BMC Gastroenterology
author_facet Jan Yi-Yin
Hwang Tsann-Long
Chao Tzu-Chieh
Wu Pei-Yu
Yeh Chun-Nan
Lee Li-Yu
Wu Ting-Jung
Chen Miin-Fu
author_sort Jan Yi-Yin
title Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
title_short Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
title_full Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
title_fullStr Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
title_full_unstemmed Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
title_sort surgical treatment and prognostic analysis for gastrointestinal stromal tumors (gists) of the small intestine: before the era of imatinib mesylate
publisher BMC
series BMC Gastroenterology
issn 1471-230X
publishDate 2006-10-01
description <p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and identify predictors for long-term disease-free survival (DFS) and overall survival (OS) to clarify the difference between high- and low-risk patients.</p> <p>Methods</p> <p>The clinicopathologic and follow-up records of 100 small intestine GIST patients who were treated at Chung Gung Memorial Hospital between 1983 and 2002 were retrospectively reviewed. Clinical and pathological factors were assessed for long-term DFS and OS by using a univariate log-rank test and a multivariate Cox proportional hazard model.</p> <p>Results</p> <p>The patients included 52 men and 48 women. Their ages ranged from 27 to 82 years. Among the 85 patients who underwent curative resection, 44 (51.8%) developed disease recurrence (liver metastasis was the most common form of recurrence). The follow-up period ranged from 5 to 202 months (median: 33.2 months). The 1-, 3-, and 5-year DFS and OS rates were 85.2%, 53.8%, and 43.7%, and 91.5%, 66.6%, and 50.5%, respectively. Using multivariate analysis, it was found that high tumor cellularity, mitotic count >5/50 high-power field, and a Ki-67 index ≧10% were three independent factors that were inversely associated with DFS. However, absence of tumor perforation, mitotic count < 5/50 high power field, and tumor with low cellularity were predictors of long-term favorable OS.</p> <p>Conclusion</p> <p>Tumors with low cellularity, low mitotic count, and low Ki-67 index, which indicate low risk, predict a more favorable DFS for small intestine GIST patients undergoing curative resection. Absence of tumor perforation with low mitotic count and low cellularity, which indicates low risk, can predict long-term OS for small intestine GIST patients who have undergone curative resection.</p>
url http://www.biomedcentral.com/1471-230X/6/29
work_keys_str_mv AT janyiyin surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT hwangtsannlong surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT chaotzuchieh surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT wupeiyu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT yehchunnan surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT leeliyu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT wutingjung surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
AT chenmiinfu surgicaltreatmentandprognosticanalysisforgastrointestinalstromaltumorsgistsofthesmallintestinebeforetheeraofimatinibmesylate
_version_ 1724537532961521664